TY  - JOUR
AU  - Yew, Y.W.*
AU  - Dinish, U.S.*
AU  - Yu Kuan, A.H.*
AU  - Li, X.*
AU  - Dev, K.*
AU  - Ebrahim Attia, A.B.*
AU  - Bi, R.*
AU  - Moothanchery, M.*
AU  - Balasundaram, G.*
AU  - Aguirre, J.*
AU  - Ntziachristos, V.
AU  - Olivo, M.*
AU  - Guan Thng, S.T.*
C1  - 59513
C2  - 48889
CY  - 360 Park Avenue South, New York, Ny 10010-1710 Usa
SP  - 1121-1123
TI  - Raster-scanning optoacoustic mesoscopy (RSOM) imaging as an objective disease severity tool in atopic dermatitis patients.
JO  - J. Am. Acad. Dermatol.
VL  - 84
IS  - 4
PB  - Mosby-elsevier
PY  - 2021
SN  - 0190-9622
ER  - 

TY  - JOUR
AB  - Purpose of Review Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs.Recent Findings Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research.Summary Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.
AU  - Guttman-Yassky, E.*
AU  - Brunner, P.M.*
AU  - Neumann, A.U.
AU  - Khattri, S.*
AU  - Pavel, A.B.*
AU  - Malik, K.A.*
AU  - Singer, G.K.*
AU  - Baum, D.*
AU  - Gilleaudeau, P.*
AU  - Sullivan-Whalen, M.*
AU  - Rose, S.*
AU  - Jim On, S.*
AU  - Li, X.*
AU  - Fuentes-Duculan, J.*
AU  - Estrada, Y.*
AU  - Garcet, S.*
AU  - Traidl-Hoffmann, C.
AU  - Krueger, J.G.*
AU  - Lebwohl, M.G.*
C1  - 52763
C2  - 44478
CY  - 233 Spring St, New York, Ny 10013 Usa
SP  - 872-881.e6
TI  - Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
JO  - J. Am. Acad. Dermatol.
VL  - 78
IS  - 5
PB  - Springer
PY  - 2018
SN  - 0190-9622
ER  - 

TY  - JOUR
AB  - BACKGROUND: Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking. OBJECTIVE: To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient. METHODS: A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion. RESULTS: We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy. LIMITATIONS: Our work is a consensus statement, not a systematic review. CONCLUSION: The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.
AU  - Simpson, E.L.*
AU  - Bruin-Weller, M.*
AU  - Flohr, C.*
AU  - Ardern-Jones, M.R.*
AU  - Barbarot, S.*
AU  - Deleuran, M.*
AU  - Bieber, T.*
AU  - Vestergaard, C.*
AU  - Brown, S.J.*
AU  - Cork, M.J.*
AU  - Drucker, A.M.*
AU  - Eichenfield, L.F.*
AU  - Foelster-Holst, R.*
AU  - Guttman-Yassky, E.*
AU  - Nosbaum, A.*
AU  - Reynolds, N.J.*
AU  - Silverberg, J.I.*
AU  - Schmitt, J.*
AU  - Seyger, M.M.B.*
AU  - Spuls, P.I.*
AU  - Stalder, J.F.*
AU  - Su, J.C.*
AU  - Takaoka, R.*
AU  - Traidl-Hoffmann, C.
AU  - Thyssen, J.P.*
AU  - van der Schaft, J.*
AU  - Wollenberg, A.*
AU  - Irvine, A.D.*
AU  - Paller, A.S.*
C1  - 51719
C2  - 43467
CY  - New York
SP  - 623-633
TI  - When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
JO  - J. Am. Acad. Dermatol.
VL  - 77
IS  - 4
PB  - Mosby-elsevier
PY  - 2017
SN  - 0190-9622
ER  - 

TY  - JOUR
AB  - BACKGROUND: Topical calcineurin inhibitors are licensed for the treatment of atopic dermatitis; however, the efficacy of tacrolimus in cutaneous lupus erythematosus (CLE) has only been shown in single case reports. OBJECTIVE: In a multicenter, randomized, double-blind, vehicle-controlled trial, we sought to evaluate the efficacy of tacrolimus 0.1% ointment for skin lesions in CLE. METHODS: Thirty patients (18 female, 12 male) with different subtypes of CLE were included, and two selected skin lesions in each patient were treated either with tacrolimus 0.1% ointment or vehicle twice daily for 12 weeks. The evaluation included scoring of clinical features, such as erythema, hypertrophy/desquamation, edema, and dysesthesia. RESULTS: Significant improvement (P < .05) was seen in skin lesions of CLE patients treated with tacrolimus 0.1% ointment after 28 and 56 days, but not after 84 days, compared with skin lesions treated with vehicle. Edema responded most rapidly to tacrolimus 0.1% ointment and the effect was significant (P < .001) in comparison to treatment with vehicle after 28 days. Clinical score changes in erythema also showed remarkable improvement (P < .05) after 28 days, but not after 56 and 84 days. Moreover, patients with lupus erythematosus tumidus revealed the highest degree of improvement. None of the patients with CLE demonstrated any major side effects. LIMITATIONS: The study was limited by the small sample size. CONCLUSION: Explorative subgroup analyses revealed that topical application of tacrolimus 0.1% ointment may provide at least temporary benefit, especially in acute, edematous, non-hyperkeratotic lesions of CLE patients, suggesting that calcineurin inhibitors may represent an alternative treatment for the various disease subtypes.
AU  - Kühn-Steven, A.*
AU  - Gensch, K.*
AU  - Haust, M.*
AU  - Schneider, S.W.*
AU  - Bonsmann, G.*
AU  - Gaebelein-Wissing, N.*
AU  - Lehmann, P.*
AU  - Wons, A.*
AU  - Reitmeir, P.
AU  - Ruland, V.*
AU  - Luger, T.A.*
AU  - Ruzicka, T.*
C1  - 5369
C2  - 28664
SP  - 54-64
TI  - Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial.
JO  - J. Am. Acad. Dermatol.
VL  - 65
IS  - 1
PB  - American Academy of Dermatology, Inc.
PY  - 2011
SN  - 0190-9622
ER  - 

TY  - JOUR
AB  - Sentinel lymph node biopsy (SLNB) is a widely accepted procedure to accurately stage patients with melanoma. However, there is no consensus concerning the practical consequences of a positive SLN, since a survival benefit of a complete lymph node dissection (CLND) has not yet been demonstrated. We wondered whether we could identify a subgroup of patients with metastatic involvement of the SLN who could be excluded from the recommendation to undergo CLND. At the Department of Dermatology at the University of Munich, a total of 213 patients with metastatic SLNs (24.9%) were identified among 854 patients who had undergone SLNB between 1996 and 2007. All SLN-positive patients had been advised to have CLND. Survival analyses were performed by using the Kaplan-Meier approach. A total of 176 (82.6%) of 213 SLN-positive patients underwent CLND. In this group, 26 patients (14.8%) showed metastatic disease in non-sentinel lymph nodes (NSLN). The 5-year overall survival (OS) was 26.1% in NSLN-positive patients and 74% in NSLN-negative patients. SLN-positive patients who refused CLND had a better prognosis than patients with CLND. Breslow tumor thickness was significantly associated with positive CLND status with higher median values in CLND-positive than CLND-negative patients (3.03 vs 2.22 mm).The subgroup of patients with metastatic disease in CLND may have been too small to reach statistical significance for other tumor- or patient-related parameters. Mitotic indices of the primary melanomas had not been determined in this retrospective study; thus a possible correlation with lymph node status could not be tested. Among SLN-positive patients, the presence of metastatic NSLN is a highly significant poor prognostic factor. Tumor thickness is a significant prognostic parameter for positive CLND status and might be considered in the decision to perform CLND in case of metastatic SLN.
AU  - Kunte, C.*
AU  - Geimer, T.*
AU  - Baumert, J.J.
AU  - Konz, B.*
AU  - Volkenandt, M.*
AU  - Flaig, M.*
AU  - Ruzicka, T.*
AU  - Berking, C.*
AU  - Schmid-Wendtner, M.H.*
C1  - 5785
C2  - 28945
CY  - New York, USA
SP  - 655-662
TI  - Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes.
JO  - J. Am. Acad. Dermatol.
VL  - 64
IS  - 4
PB  - Mosby-Elsevier
PY  - 2011
SN  - 0190-9622
ER  - 

TY  - JOUR
AB  - We report the case of a 45-year-old Caucasian woman suffering from cutaneous myiasis. With the use of scanning electron microscopy, we placed special focus on the mechanisms by which Dermatobia hominis can fasten securely within the human skin.
AU  - Möhrenschlager, M.*
AU  - Mempel, M.*
AU  - Weichenmeier, I.
AU  - Engst, R.*
AU  - Ring, J.*
AU  - Behrendt, H.
C1  - 1200
C2  - 24728
SP  - 716-718
TI  - Scanning electron microscopy of Dermatobia hominis reveals cutaneous anchoring features.
JO  - J. Am. Acad. Dermatol.
VL  - 57
IS  - 4
PB  - Mosby
PY  - 2007
SN  - 0190-9622
ER  -